Additionally, MEK inhibition can be associated with notable adverse effects, leading to dose reductions or discontinuation of therapy, thereby limiting its long-term use for the treatment of NF1-associated ADHD and ASD (86). Here, MAP2K7 is linked to attention deficit-hyperactivity disorder.